RELEASE: Macrogen Introduces PacBio 'Revio' in Korea and for the First Time in Asia

Korea April 10, 2023.

Revio is the new equipment that improves data performance and is capable of analyzing the complete genome of up to 1,300 people per year. With the ability to improve genome-wide analyzes in a quantitative and qualitative way, it is expected to help treat rare and incurable diseases.

The third generation long read sequencing system, which increases data throughput by 15 times compared to existing equipment, has been introduced for the first time in Korea. Macrogen, a biotechnology company specializing in precision medicine, announced on the 4th that it had installed the next-generation genome analysis system 'PacBio Revio' for the first time in Asia. Macrogen has completed the installation of Revio at the Genome Center located in Geumcheon-gu, Seoul, and plans to expand its service portfolio in the first half of this year by focusing on the bio-red (medical, healthcare, pharmaceutical) and bio-green (agricultural, livestock, and food) sectors. Recently launched Revio by Macrogen, is a high throughput long read assay kit from Pacific Biosciences of California, Inc. (PacBio), a sequencing solutions company. Long read sequencing, which can read more than tens of thousands of base pairs continuously, detects structural changes in DNA and enables precise analysis, which will help overcome rare and incurable diseases, as well as analyze genomes from various animals and plants whose genomes have yet to be identified. Revio is an analysis system equipped with the advantages of long read sequencing, as well as high capacity and high speed. It can process up to 1,300 battlefield genomes per year by increasing data throughput 15 times compared to existing equipment. Macrogen's introduction of Revio is expected to help treat many incurable diseases, including the fight against cancer , through quantitative and qualitative improvements in the analysis of the whole genome. In particular, with the recently announced Korean government policy to encourage bio-industry, the development of genome analysis technology is expected to have a ripple effect on the growth of the Korean bio-sector. Macrogen CEO Kim Chang-hoon, has commented that Macrogen is leading changes in the red biologics sectors for the treatment of rare and incurable diseases through the introduction of genome analysis technology that goes beyond existing boundaries, as well as the green biologics sector through the analysis of microbiome and metagenome. Christian Henry, President and CEO of PacBio is very pleased to say that Macrogen has introduced the Revio system for the first time in Asia. Pacbio and Macrogen show strong cooperation to lead new scientific discoveries. Meanwhile, Macrogen continues to invest in biodiversity community analysis, also called metagenome, used to analyze samples from the human intestine, skin and oral cavity (among others). . Following the acquisition of a national patent called "Health Information Forecasting Method and Analysis Device Using Microbiome" in February, the company is strengthening its microbiome business portfolio by developing new products based on its expertise in analysis. metagenome.

Contact Contact name: Ana Contact description: Ana Contact telephone number: 635832160